Please login to the form below

Not currently logged in
Email:
Password:

Novartis' orphan drug Tasigna wins EU expanded indication

The CML medication can now treat paediatric patients

Novartis

Novartis has claimed another regulatory milestone for its chronic myeloid leukaemia (CML) drug Tasigna (nilotinib), winning approval for its use to treat children in the EU.

The European Commission approved the drug as a first-line treatment for paediatric patients with newly diagnosed Philadelphia chromosome-positive CML in the chronic phase (Ph+ CML-CP).

In addition, the EC also gave the go-ahead for the same indication as a second-line treatment in paediatric patients with resistance or intolerance to prior therapy including its own Gilvec/Gleevec (imatinib).

Bruno Strigini, chief executive officer, Novartis Oncology, said: “Treatment options for children with CML have historically been limited, and with this new indication an unmet need has been addressed.”

CML is a type of cancer in which the body produces cancerous white blood cells and almost all CML patients have an abnormality known as the Philadelphia chromosome, which causes malignant white blood cells to proliferate.

The disease is responsible for approximately 10-15% of all adult cases of leukaemia, with an incidence of one-to-two cases per 100,000 people per year worldwide.

The EC’s decision to expand Tasigna’s indications to include the treatment of children came on the back of two studies in paediatric patients with Ph+CML-CP, which had been part of a formal “paediatric investigation plan” agreed with the European Medicines Agency (EMA).

In the studies, patients - aged two-18 years - with newly diagnosed CML achieved a major molecular response rate of 60% at 12 cycles. In patients with resistance or intolerance to prior therapy, the MMR rate was just under 41% at 12 cycles.

Strigini added: “Data from two prospective studies demonstrated Tasigna is safe and effective in patients as young as two years old, which is consistent with the established safety profile of Tasigna in adults.”

The approval is the latest in a series of regulatory milestones for the orphan drug. Earlier this year Tasigna became the first and only drug of its kind to include information on stopping therapy in adult patients with Ph+ CML-CP in both the first-line setting and after switching from imatinib in the EU label.

Article by
Gemma Jones

22nd November 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics